comparemela.com
Home
Live Updates
Biogen Inc.: Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinsons Disease : comparemela.com
Biogen Inc.: Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson's Disease
AL01811 is a preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease modifying treatment for Parkinson's DiseaseAlectos to receive a $15 million upfront payment and is eligible
Related Keywords
Cambridge ,
Cambridgeshire ,
United Kingdom ,
British ,
Walter Gilbert ,
Charles Weissmann ,
Heinz Schaller ,
Ernest Mceachern ,
Ashleigh Koss ,
Priya Singhal ,
Mike Hencke ,
Kenneth Murray ,
Exchange Commission ,
Youtube ,
Linkedin ,
Parkinson Foundation ,
Twitter ,
Facebook ,
Nasdaq ,
British Columbia ,
Alectos Therapeutics ,
Interim Head ,
Sir Kenneth Murray ,
Nobel Prize ,
Healthy Lives ,
Private Securities Litigation Reform Act ,
Biogen ,
Electos ,
Herapeutics ,
Nnounce ,
License ,
Collaboration ,
Agreement ,
L01811 ,
Novel ,
Ba2 ,
Inhibitor ,
Potential ,
Treatment ,
Parkinson ,
Disease ,
comparemela.com © 2020. All Rights Reserved.